MIRA received confirmation that its three lead drug candidates are not controlled substances, supporting continued development. The programs still need more study, so this does not show that they work or will reach patients.
That gives MIRA a clearer path to keep working on three programs. But each still needs more study. Ketamir-2 is moving toward Phase 2, MIRA-55 aims to file in early 2027, and SKNY-1 remains in preclinical study.
Follow MIRA Pharmaceuticals (MIRA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MIRA